Literature DB >> 29895698

Thyroid hormone receptor β1 stimulates ABCB4 to increase biliary phosphatidylcholine excretion in mice.

Julien Gautherot1, Thierry Claudel1, Frans Cuperus1, Claudia Daniela Fuchs1, Thomas Falguières2, Michael Trauner3.   

Abstract

The ATP-binding cassette transporter ABCB4/MDR3 is critical for biliary phosphatidylcholine (PC) excretion at the canalicular membrane of hepatocytes. Defective ABCB4 gene expression and protein function result in various cholestatic liver and bile duct injuries. Thyroid hormone receptor (THR) is a major regulator of hepatic lipid metabolism; we explored its potential role in ABCB4 regulation. Thyroid hormone T3 stimulation to human hepatocyte models showed direct transcriptional activation of ABCB4 in a dose- and time-dependent manner. To determine whether THRβ1 (the main THR isoform of the liver) is involved in regulation, we tested THRβ1-specific agonists (e.g., GC-1, KB-141); these agonists resulted in greater stimulation than the native hormone. KB-141 activated hepatic ABCB44 expression in mice, which enhanced biliary PC secretion in vivo. We also identified THR response elements 6 kb upstream of the ABCB4 locus that were conserved in humans and mice. Thus, T3-via THRβ1 as a novel transcriptional activator regulates ABCB4 to increase ABCB4 protein levels at the canalicular membrane and promote PC secretion into bile. These findings may have important implications for understanding thyroid hormone function as a potential modifier of bile duct homeostasis and provide pharmacologic opportunities to improve liver function in hepatobiliary diseases caused by low ABCB4 expression.
Copyright © 2018 Gautherot et al.

Entities:  

Keywords:  ABC transporters; bile; nuclear receptor; phospholipids; transcription

Mesh:

Substances:

Year:  2018        PMID: 29895698      PMCID: PMC6121935          DOI: 10.1194/jlr.M084145

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  50 in total

1.  Identical gene regulation patterns of T3 and selective thyroid hormone receptor modulator GC-1.

Authors:  Chaoshen Yuan; Jean Z H Lin; Douglas H Sieglaff; Steven D Ayers; Frances Denoto-Reynolds; John D Baxter; Paul Webb
Journal:  Endocrinology       Date:  2011-11-08       Impact factor: 4.736

Review 2.  Thyroid hormone receptor mutations and disease: beyond thyroid hormone resistance.

Authors:  Sheue-yann Cheng
Journal:  Trends Endocrinol Metab       Date:  2005 May-Jun       Impact factor: 12.015

3.  Cardiac ion channel expression and contractile function in mice with deletion of thyroid hormone receptor alpha or beta.

Authors:  B Gloss; S Trost; W Bluhm; E Swanson; R Clark; R Winkfein; K Janzen; W Giles; O Chassande; J Samarut; W Dillmann
Journal:  Endocrinology       Date:  2001-02       Impact factor: 4.736

4.  Immortalized human hepatocytes as a tool for the study of hepatocytic (de-)differentiation.

Authors:  I J Schippers; H Moshage; H Roelofsen; M Müller; H S Heymans; M Ruiters; F Kuipers
Journal:  Cell Biol Toxicol       Date:  1997-07       Impact factor: 6.691

5.  Identification of a nuclear receptor for bile acids.

Authors:  M Makishima; A Y Okamoto; J J Repa; H Tu; R M Learned; A Luk; M V Hull; K D Lustig; D J Mangelsdorf; B Shan
Journal:  Science       Date:  1999-05-21       Impact factor: 47.728

6.  Bezafibrate stimulates canalicular localization of NBD-labeled PC in HepG2 cells by PPARalpha-mediated redistribution of ABCB4.

Authors:  Junichi Shoda; Yoichi Inada; Atsutoshi Tsuji; Hiroshi Kusama; Tetsuya Ueda; Tadashi Ikegami; Hiroshi Suzuki; Yuichi Sugiyama; David E Cohen; Naomi Tanaka
Journal:  J Lipid Res       Date:  2004-07-16       Impact factor: 5.922

Review 7.  Extrahepatic autoimmune conditions associated with primary biliary cirrhosis.

Authors:  Annarosa Floreani; Irene Franceschet; Nora Cazzagon; Alice Spinazzè; Alessandra Buja; Patrizia Furlan; Vincenzo Baldo; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2015-06       Impact factor: 8.667

Review 8.  Thyroid disease and the heart.

Authors:  Irwin Klein; Sara Danzi
Journal:  Circulation       Date:  2007-10-09       Impact factor: 29.690

9.  Therapeutic effect of bezafibrate against biliary damage: a study of phospholipid secretion via the PPARalpha-MDR3 pathway.

Authors:  M Nakamuta; T Fujino; R Yada; K Yasutake; T Yoshimoto; N Harada; M Yada; N Higuchi; M Kato; M Kohjima; A Taketomi; Y Maehara; T Nishinakagawa; K Machida; K Matsunaga; M Nakashima; K Kotoh; M Enjoji
Journal:  Int J Clin Pharmacol Ther       Date:  2010-01       Impact factor: 1.366

10.  Bile duct stone procedures are more frequent in patients with hypothyroidism. A large, registry-based, cohort study in Finland.

Authors:  Johanna Laukkarinen; Juhani Sand; Ville Autio; Isto Nordback
Journal:  Scand J Gastroenterol       Date:  2010       Impact factor: 2.423

View more
  4 in total

1.  Hepatic thyroid hormone receptor β1 agonism: good for lipids, good for bile?

Authors:  Paul A Dawson; Paolo Parini
Journal:  J Lipid Res       Date:  2018-07-31       Impact factor: 5.922

Review 2.  Targeting Thyroid Hormone/Thyroid Hormone Receptor Axis: An Attractive Therapy Strategy in Liver Diseases.

Authors:  Qianyu Tang; Min Zeng; Linxi Chen; Nian Fu
Journal:  Front Pharmacol       Date:  2022-06-02       Impact factor: 5.988

3.  The Thyromimetic Sobetirome (GC-1) Alters Bile Acid Metabolism in a Mouse Model of Hepatic Cholestasis.

Authors:  Karis Kosar; Pamela Cornuet; Sucha Singh; Silvia Liu; Kari Nejak-Bowen
Journal:  Am J Pathol       Date:  2020-03-20       Impact factor: 4.307

Review 4.  Novel therapeutic targets for cholestatic and fatty liver disease.

Authors:  Michael Trauner; Claudia Daniela Fuchs
Journal:  Gut       Date:  2021-10-06       Impact factor: 23.059

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.